U.S. markets open in 1 hour 41 minutes
  • S&P Futures

    4,273.00
    -34.75 (-0.81%)
     
  • Dow Futures

    33,912.00
    -206.00 (-0.60%)
     
  • Nasdaq Futures

    13,528.25
    -130.00 (-0.95%)
     
  • Russell 2000 Futures

    2,005.20
    -18.10 (-0.89%)
     
  • Crude Oil

    86.45
    -0.08 (-0.09%)
     
  • Gold

    1,783.10
    -6.60 (-0.37%)
     
  • Silver

    19.76
    -0.32 (-1.59%)
     
  • EUR/USD

    1.0166
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    2.8240
    0.0000 (0.00%)
     
  • Vix

    20.50
    +0.55 (+2.76%)
     
  • GBP/USD

    1.2064
    -0.0030 (-0.25%)
     
  • USD/JPY

    135.1460
    +0.9310 (+0.69%)
     
  • BTC-USD

    23,754.08
    -297.34 (-1.24%)
     
  • CMC Crypto 200

    565.98
    -5.93 (-1.04%)
     
  • FTSE 100

    7,506.65
    -29.41 (-0.39%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Here's Why We Think QuidelOrtho (NASDAQ:QDEL) Is Well Worth Watching

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks with a good story, even if those businesses lose money. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses.

So if you're like me, you might be more interested in profitable, growing companies, like QuidelOrtho (NASDAQ:QDEL). Now, I'm not saying that the stock is necessarily undervalued today; but I can't shake an appreciation for the profitability of the business itself. While a well funded company may sustain losses for years, unless its owners have an endless appetite for subsidizing the customer, it will need to generate a profit eventually, or else breathe its last breath.

See our latest analysis for QuidelOrtho

QuidelOrtho's Improving Profits

In the last three years QuidelOrtho's earnings per share took off like a rocket; fast, and from a low base. So the actual rate of growth doesn't tell us much. As a result, I'll zoom in on growth over the last year, instead. QuidelOrtho has grown its trailing twelve month EPS from US$22.45 to US$24.04, in the last year. That's a modest gain of 7.1%.

I like to take a look at earnings before interest and (EBIT) tax margins, as well as revenue growth, to get another take on the quality of the company's growth. On the one hand, QuidelOrtho's EBIT margins fell over the last year, but on the other hand, revenue grew. So it seems the future my hold further growth, especially if EBIT margins can stabilize.

The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.

earnings-and-revenue-history
earnings-and-revenue-history

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. To that end, right now and today, you can check our visualization of consensus analyst forecasts for future QuidelOrtho EPS 100% free.

Are QuidelOrtho Insiders Aligned With All Shareholders?

I like company leaders to have some skin in the game, so to speak, because it increases alignment of incentives between the people running the business, and its true owners. As a result, I'm encouraged by the fact that insiders own QuidelOrtho shares worth a considerable sum. Notably, they have an enormous stake in the company, worth US$412m. I would find that kind of skin in the game quite encouraging, if I owned shares, since it would ensure that the leaders of the company would also experience my success, or failure, with the stock.

It means a lot to see insiders invested in the business, but I find myself wondering if remuneration policies are shareholder friendly. Well, based on the CEO pay, I'd say they are indeed. For companies with market capitalizations between US$2.0b and US$6.4b, like QuidelOrtho, the median CEO pay is around US$6.6m.

QuidelOrtho offered total compensation worth US$5.5m to its CEO in the year to . That comes in below the average for similar sized companies, and seems pretty reasonable to me. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. I'd also argue reasonable pay levels attest to good decision making more generally.

Does QuidelOrtho Deserve A Spot On Your Watchlist?

One positive for QuidelOrtho is that it is growing EPS. That's nice to see. The fact that EPS is growing is a genuine positive for QuidelOrtho, but the pretty picture gets better than that. With a meaningful level of insider ownership, and reasonable CEO pay, a reasonable mind might conclude that this is one stock worth watching. It is worth noting though that we have found 2 warning signs for QuidelOrtho that you need to take into consideration.

Of course, you can do well (sometimes) buying stocks that are not growing earnings and do not have insiders buying shares. But as a growth investor I always like to check out companies that do have those features. You can access a free list of them here.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.